Education
About Us
Working with TipRanks
Follow Us
Daiichi Sankyo Company Limited (JP:4568)
:4568
RESEARCH TOOLSreports
4568 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥3,036.00 - ¥6,257.00
Previous CloseN/A
Volume4.34M
Average Volume (3M)6.57M
Market Cap
$5.83T
Enterprise Value¥7.64T
Total Cash (Recent Filing)¥126.42B
Total Debt (Recent Filing)¥255.35B
Price to Earnings (P/E)24.1
Beta0.86
Next Earnings
Apr 24, 2025EPS Estimate
19.91Last Dividend Ex-Date
Mar 28, 2025Dividend Yield1.8%
Share Statistics
EPS (TTM)32.82
Shares Outstanding1,908,322,100
10 Day Avg. Volume9,062,060
30 Day Avg. Volume6,570,433
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5,732.76Price Target Upside62.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Daiichi Sankyo Company News
PremiumCompany Announcements
Daiichi Sankyo Reports Strong Fiscal Year Growth
PremiumCompany Announcements
Daiichi Sankyo Reports Robust Q3 Earnings Performance
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalFDA has approved anticancer candidate Dato-DXd for breast cancer, which is considered a positive surprise by the market.
Market ExpectationsExpectations for Dato's first US approval for breast cancer are high, supported by approval from Japanese authorities.
Valuation And EarningsDaiichi Sankyo is trading at an attractive valuation, with expectations of the company's EPS expanding over the next five years.
Bears Say
Price Control MeasuresThe US has implemented price control measures for Medicare under Biden administration, DS anticipates this trend to continue under Trump.
Stock DeclineDaiichi's shares have declined by about 1/3 since the company reported disappointing data from a lung cancer study.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
12.11%
Mutual Funds
0.02% Other Institutional Investors
78.92% Public Companies and
Individual Investors
4568 FAQ
What was Daiichi Sankyo Company Limited’s price range in the past 12 months?
Daiichi Sankyo Company Limited lowest stock price was ¥3036.00 and its highest was ¥6257.00 in the past 12 months.
What is Daiichi Sankyo Company Limited’s market cap?
Daiichi Sankyo Company Limited’s market cap is $5.83T.
When is Daiichi Sankyo Company Limited’s upcoming earnings report date?
Daiichi Sankyo Company Limited’s upcoming earnings report date is Apr 24, 2025 which is 4 days ago.
How were Daiichi Sankyo Company Limited’s earnings last quarter?
Daiichi Sankyo Company Limited released its earnings results on Apr 25, 2025. The company reported ¥46.31 earnings per share for the quarter, beating the consensus estimate of ¥19.458 by ¥26.852.
Is Daiichi Sankyo Company Limited overvalued?
According to Wall Street analysts Daiichi Sankyo Company Limited’s price is currently Undervalued.
Does Daiichi Sankyo Company Limited pay dividends?
Daiichi Sankyo Company Limited pays a Annually dividend of ¥30 which represents an annual dividend yield of 1.8%. See more information on Daiichi Sankyo Company Limited dividends here
What is Daiichi Sankyo Company Limited’s EPS estimate?
Daiichi Sankyo Company Limited’s EPS estimate is 19.91.
How many shares outstanding does Daiichi Sankyo Company Limited have?
Daiichi Sankyo Company Limited has 1,908,322,100 shares outstanding.
What happened to Daiichi Sankyo Company Limited’s price movement after its last earnings report?
Daiichi Sankyo Company Limited reported an EPS of ¥46.31 in its last earnings report, beating expectations of ¥19.458. Following the earnings report the stock price went up 6.242%.
Which hedge fund is a major shareholder of Daiichi Sankyo Company Limited?
Currently, no hedge funds are holding shares in JP:4568
---
Company Description
Daiichi Sankyo Company Limited
Daiichi Sankyo Company, Limited is a leading global pharmaceutical company headquartered in Tokyo, Japan. It operates in the healthcare sector, focusing primarily on the research, development, and marketing of a wide range of pharmaceuticals. The company's core products include innovative medicines for cardiovascular, oncology, and rare diseases, as well as generic pharmaceuticals.
---
4568 Company Deck
---
4568 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a robust financial performance with significant revenue and profit growth, driven by strong product sales and successful patent settlements. However, slight downward adjustments in sales forecasts and potential financial uncertainties were noted.Read More>---
4568 Stock 12 Month Forecast
Average Price Target
¥5,732.76
▲(62.72% Upside)
Technical Analysis
Sumitomo Dainippon Pharma Co
―
Astellas Pharma
―
Chugai Pharmaceutical Co
―
Eisai Co
―
Takeda Pharmaceutical Co
―
Best Analysts Covering 4568
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-29.92%
reiterated a buy rating 2 months ago
Copying Seiji Wakao's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -29.92% per trade.
---